NCT03236428: Phase 2: Phase II Study of the CD38 Antibody Daratumumab MGUS / Smoldering Myeloma SMM

NCT03236428: Phase 2: Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

This research study is studying a drug as a possible treatment for Monoclonal Gammopathy of Unknown Significance (MGUS) or Smoldering Multiple Myeloma (SMM).

The drug involved in this study is:

-Daratumumab

Sponsor

Dana-Farber Cancer Institute

Collaborators

Janssen Pharmaceuticals

Multiple Myeloma Research Consortium

Blood Cancer Research Partnership

The Leukemia and Lymphoma Society

Information provided by (Responsible Party)

Irene Ghobrial, MD, Dana-Farber Cancer Institute

---

ClinicalTrials.gov Identifier: NCT03236428

Official Title: A Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

First Posted: August 1, 2017

Click here to see details on ClinicalTrials.gov

---

Drug: Daratumumab

---

Locations

United States, California

United States, Colorado

United States, Massachusetts

United States, Michigan